Oncotarget

Clinical Research Papers:

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience

Marcus Vetter _, Spyridon Fokas, Ewelina Biskup, Thomas Schmid, Fabienne Schwab, Andreas Schoetzau, Uwe Güth, Christoph Rochlitz and Rosanna Zanetti-Dällenbach

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:75617-75626. https://doi.org/10.18632/oncotarget.18118

Metrics: PDF 1497 views  |   HTML 2930 views  |   ?  


Abstract

Marcus Vetter1,*, Spyridon Fokas2,*, Ewelina Biskup3,7, Thomas Schmid4, Fabienne Schwab2, Andreas Schoetzau2, Uwe Güth5, Christoph Rochlitz1 and Rosanna Zanetti-Dällenbach6

1 Department of Medical Oncology, University Hospital Basel, Basel, Switzerland

2 Women’s Hospital,University Hospital Basel, Basel, Switzerland

3 Department of Internal Medicine, University Hospital Basel, Basel, Switzerland

4 The Royal Marsden Hospital, London, United Kingdom

5 Brust-Zentrum Zurich, Zurich, Switzerland

6 Sankt Claraspital, Basel, Switzerland

7 Shanghai University of Medicine and Health Sciences, Department of Basic Medical College, Shanghai, PR China

* These authors have contributed equally to this work

Correspondence to:

Marcus Vetter, email:

Keywords: early breast cancer, triple negative breast cancer, chemotherapy, carboplatin, platinum-based chemotherapy

Received: November 30, 2016 Accepted: April 10, 2017 Published: May 23, 2017

Abstract

Background: Anthracycline- and taxane-based adjuvant chemotherapies are the most frequently used systemic treatments for women with triple negative breast cancer (TNBC). Adding platinum derivatives in the neo-adjuvant setting has been shown to not only improve the pCR rates, but also the 3 year DFS for TNBC patients; however, data on platinum derivatives in the adjuvant setting are limited.

Methods: We conducted a retrospective, single-center study in a Swiss breast cancer cohort to evaluate the role of carboplatin in addition to standard adjuvant therapy (anthracyclines and/ or taxanes) in early TNBC patients. All patients with stage I-III TNBC who underwent primary breast surgery between 2004 and 2014 were included.

Results: Eighty-three patients were included in the analysis. Stage and grade were well balanced between patients treated with standard chemotherapy (N=54; cohort A) or standard chemotherapy plus carboplatin (N=29; cohort B). The median time to local relapse (LRFS) was 15.0 months in cohort A versus 16.0 months in cohort B (p=0.655). The median time to distant relapse (DRFS) was 29.5 months in cohort A versus 25.0 months in cohort B (p=0.606) There was also no difference in overall survival between the two cohorts (mean overall survival 98 and 91 months, respectively; p=0.208).

Discussion: Our data suggest that in an unselected cohort of early TNBC patients, the addition of carboplatin in the adjuvant setting may not be beneficial with respect to relapse-free and overall survival. Further prospective trials to evaluate the addition of platinum in the adjuvant setting are warranted, especially to define subgroups of TNBC patients, which might benefit from carboplatin therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18118